HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.

AbstractOBJECTIVE:
To assess the long-term efficacy and safety of conventional radiotherapy (RT) in the control of acromegaly according to recent stringent criteria of cure.
DESIGN:
A retrospective longitudinal study.
PATIENTS AND METHODS:
Forty-seven patients with active acromegaly were treated with conventional RT between 1982 and 1994. All patients were first operated on and successively irradiated at a dose of 45-50 Gy in 25-28 fractions for persistent (n = 40) or recurrent (n = 7) disease.
MEASUREMENTS:
Long-term GH/IGF-I secretion and local tumour control were evaluated regularly, and possible side-effects were searched for systematically, especially in terms of secondary endocrine dysfunction. Biochemical cure of acromegaly was defined by glucose-suppressed plasma GH levels below 1 microg/l during an oral glucose tolerance test (OGTT) and normal age-corrected IGF-I values.
RESULTS:
The 5-, 10- and 15-year overall survival rates were 98%, 95% and 93%, respectively. Suppression of GH during OGTT was seen in 9% of patients at 2 years, 29% at 5 years, 52% at 10 years, and 77% at 15 years. Age-corrected IGF-I levels were normal in 8% of patients 2 years after RT, and this proportion increased to 23%, 42% and 61% after 5, 10 and 15 years, respectively. Normalization of GH/IGF-I mainly depended on pre-RT levels. Local tumour control was 95% at 5, 10 and 15 years after treatment. Late toxicity was mainly represented by progressive hypopituitarism, which was present in 33% of patients at baseline and increased to 57%, 78% and in 85% of patients at 5 10 and 15 years after RT, respectively.
CONCLUSION:
Conventional RT is effective in the long-term control of GH-secreting pituitary adenomas, although with a high prevalence of progressive hypopituitarism. At present, it remains a suitable option in acromegalic patients uncontrolled by surgery or medical therapy.
AuthorsGiuseppe Minniti, Marie-Lise Jaffrain-Rea, Mattia Osti, Vincenzo Esposito, Antonio Santoro, Francesca Solda, Patrizia Gargiulo, Guido Tamburrano, Riccardo Maurizi Enrici
JournalClinical endocrinology (Clin Endocrinol (Oxf)) Vol. 62 Issue 2 Pg. 210-6 (Feb 2005) ISSN: 0300-0664 [Print] England
PMID15670198 (Publication Type: Journal Article)
Chemical References
  • Insulin-Like Growth Factor I
  • Growth Hormone
Topics
  • Acromegaly (blood, mortality, radiotherapy)
  • Adenoma (metabolism, mortality, radiotherapy)
  • Adult
  • Female
  • Follow-Up Studies
  • Glucose Tolerance Test
  • Growth Hormone (metabolism)
  • Humans
  • Insulin-Like Growth Factor I (analysis)
  • Male
  • Middle Aged
  • Pituitary Neoplasms (metabolism, mortality, radiotherapy)
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: